Matching placebo to IMP

DRUG2 trials

Sponsors

Charite Universitaetsmedizin Berlin KöR

Conditions

Chronic Hand EczemaLocalized Scleroderma

Phase 2

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety deucravacitinib in patients with chronic hand eczema

CompletedCTIS2023-504298-19-00

Charite Universitaetsmedizin Berlin KöRChronic Hand Eczema

Start: 2024-07-18End: 2025-11-07Target: 57Updated: 2025-02-11

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

Not yet recruitingCTIS2025-524435-39-00

Charite Universitaetsmedizin Berlin KöRLocalized Scleroderma

Target: 78Updated: 2026-05-08